Document Detail


Tranexamic Acid: A Review of its Use in the Treatment of Hyperfibrinolysis.
MedLine Citation:
PMID:  22397329     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Tranexamic acid, a synthetic derivative of the amino acid lysine, is an antifibrinolytic agent that acts by binding to plasminogen and blocking the interaction of plasmin(ogen) with fibrin, thereby preventing dissolution of the fibrin clot. Tranexamic acid (Transamin®) is indicated in Japan for use in certain conditions with abnormal bleeding or bleeding tendencies in which local or systemic hyperfibrinolysis is considered to be involved. This article reviews the efficacy and tolerability of tranexamic acid in conditions amenable to antifibrinolytic therapy and briefly overviews the pharmacological properties of the drug. In large, randomized controlled trials, tranexamic acid generally significantly reduced perioperative blood loss compared with placebo in a variety of surgical procedures, including cardiac surgery with or without cardiopulmonary bypass, total hip and knee replacement and prostatectomy. In many instances, tranexamic acid also reduced transfusion requirements associated with surgery. It also reduced blood loss in gynaecological bleeding disorders, such as heavy menstrual bleeding, postpartum haemorrhage and bleeding irregularities caused by contraceptive implants. Tranexamic acid significantly reduced all-cause mortality and death due to bleeding in trauma patients with significant bleeding, particularly when administered early after injury. It was also effective in traumatic hyphaema, gastrointestinal bleeding and hereditary angioneurotic oedema. While it reduces rebleeding in subarachnoid haemorrhage, it may increase ischaemic complications. Pharmacoeconomic analyses predicted that tranexamic acid use in surgery and trauma would be very cost effective and potentially life saving. In direct comparisons with other marketed agents, tranexamic acid was at least as effective as ε-aminocaproic acid and more effective than desmopressin in surgical procedures. It was more effective than desmopressin, etamsylate, flurbiprofen, mefenamic acid and norethisterone, but less effective than the levonorgestrel-releasing intra-uterine device in heavy menstrual bleeding and was as effective as prednisolone in traumatic hyphaema. Tranexamic acid was generally well tolerated. Most adverse events in clinical trials were of mild or moderate severity; severe or serious events were rare. Therefore, while high-quality published evidence is limited for some approved indications, tranexamic acid is an effective and well tolerated antifibrinolytic agent.
Authors:
Paul L McCormack
Related Documents :
845879 - Dibenz[b,e]oxepinalkanoic acids as nonsteroidal antiinflammatory agents. 2. dihydro-10-...
19269819 - Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl...
20161109 - The first total synthesis of (+/-)-4-methoxydecanoic acid: a novel antifungal fatty acid.
17499989 - Novel heterocyclic thyromimetics. part 2.
2724299 - Synthesis and thromboxane synthetase inhibitory activity of di- or tetrahydrobenzo[b]th...
4084009 - Cytostatic activity in vitro of phosphonic acid derivatives.
21258689 - Reply to the 'comment on "theoretical investigations into the enantiomeric and racemic ...
21210069 - Brønsted acid sites in metal-containing solid acids: from quantification to molecular ...
9923969 - The salubrious effects of ascorbic acid on cyclophosphamide instigated lipid abnormalit...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-7
Journal Detail:
Title:  Drugs     Volume:  -     ISSN:  0012-6667     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Adis, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Use of Proteomics for Systematic Analysis of Normal And Transformed Hematopoietic Stem Cells.
Next Document:  Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-...